Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.67 |
| ▸ | TYMP | P19971 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PYGM | P11217 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62321 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL7182936 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL20875706 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL1021637 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL22992480 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL22992424 | 1.00 | TK2 (0.67) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL29509957 | 0.99 | TK2 (0.66) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL14429106 | 0.95 | TK2 (0.62) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL15691446 | 0.91 | TK2 (0.58) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL15691496 | 0.91 | TK2 (0.58) | TK2TYMPALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | claimed |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | HELIX NANOTECHNOLOGIES INC | 2025-08-28 | — | — | US | claimed |
| EP-3630985-B1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS INC (US) | 2025-08-27 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4601656-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2025-08-20 | — | — | EP | claimed |
| WO-2025122628-A1 | CIRCULARIZED RNAS AND METHODS OF MAKING THE SAME | HELIX NANOTECHNOLOGIES INC (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025081087-A1 | METHODS FOR CENTRAL NERVOUS SYSTEM NUCLEIC ACID DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025081080-A1 | COMPOSITIONS FOR CENTRAL NERVOUS SYSTEM NUCLEIC ACID DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250049950-A1 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | ARCTURUS THERAPEUTICS, INC. | 2025-02-13 | — | — | US | claimed |
| WO-2025024442-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BSEP DEFICIENCY | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2008109500-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING PRKCA GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| EP-1948822-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2008-07-30 | — | — | EP | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| US-20070231810-A1 | Multicomponent nucleic acid enzymes and methods for their use | SPEEDX PTY LTD (AU) | 2007-10-04 | — | — | US | claimed |
| WO-2007041774-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2007-04-19 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-6706691-B1 | BIOAVAILABILITY OF COMPOSITIONS METABOLIZED BY THE GUT P450 ISOZYMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-03-16 | — | — | US | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| EP-0795029-A1 | CHEMICAL LABELLING OF OBJECTS | Pabio (NO) | 1997-09-17 | — | — | EP | claimed |
| WO-1996017954-A1 | CHEMICAL LABELLING OF OBJECTS | PABIO (DK) | 1996-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK2 207/4885TYMP 7/4885ALDH1A1 2112/4885 |
| US-20250049950-A1 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, RNMT, RNGTT | TK2 1720/4885TYMP 2570/4885ALDH1A1 4062/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | TK2 124/4885TYMP 921/4885ALDH1A1 2668/4885 |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | IGF2BP3, SERPINC1, IGF2BP2 | TK2 1650/4885TYMP 2704/4885ALDH1A1 4110/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | TK2 3708/4885TYMP 4834/4885ALDH1A1 1020/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK2 207/4885TYMP 7/4885ALDH1A1 2112/4885 |
| US-20250270299-A1 | METHODS OF USING COMPOSITIONS COMPRISING SBI DOMAINS | C1QBP, SSB, SARNP | TK2 3025/4885TYMP 36/4885ALDH1A1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.